(Correction: An earlier version of the article stated that Akademikerpension had assessed that Coloplast could be hurt in the competition to recruit the best employees if it did not report on its tax payments on a country-by-country basis. The pension firm emphasizes that this is only the case over time if the medtech company's competition becomes more transparent, and adds that Coloplast is not suffering any recruitment losses in its current situation. The article also previously stated that Akademikerpension had attempted to push Coloplast into publicizing its national tax payments for over a year. This has been corrected, now reporting that Akademikerpension inquired whether there were any obstacles for doing so).
A year ago, Danish pension firm Akademikerpension inquired whether Coloplast knew of any potential obstacles for publicizing its tax payments in all of the countries it operates in. However, the pension firm received no clear answer.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Thousands of collaborative research papers with China pose threat to Europe, authorities worry
Research collaborations with China, including those in the life science sector, are being put under the microscope as defense authorities express concerns about Chinese espionage in Europe.
Orphazyme's creditors to vote on sales agreement at end of May
Sunday’s sales agreement between US-based Kempharm and Orphazyme will be decided on May 30, when the company’s creditors meet to vote on the proposal.
Novo Holdings establishes new firm managed by biotech veterans
Co-Founder and former CSO of Orphazyme Thomas Kirkegaard Jensen and Bo Rode Hansen, CEO of Scandion Oncology, are both involved in another secret venture backed by Novo Holdings.
Diabetes center CEO: New Eli Lilly drug is worthy opponent for Novo Nordisk's Ozempic
Allan Flyvbjerg, CEO of Steno Diabetes Center in Copenhagen, says Eli Lilly’s tirzepatide has proved itself a fierce challenger to Novo Nordisk’s newest generation of diabetes drugs.
In a world of options, Genmab's CEO chose partnerships
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.
Cell Culture Scientist/Senior Scientist 
Consultant Manager 
Director for innovative pre-clinical testing unit 
Senior Manager, Clinical Trial Budget 
IT Solution Architect for R&D and Global Quality applications 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Account Manager 
Quality System Manager 
Procurement Process Excellence Specialist 
Nordic Medical Affairs Manager 
Communications Consultant 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
Client Talent Acquisition Specialist 
Key Account Manager, Europe and Asia 
Clinical Project Manager